Case Reports in Oncology最新文献_第2页

A Case Report of Immune Checkpoint-Related Hemophagocytic Lymphohistiocytosis and Review of the Literature. 免疫检查点相关嗜血细胞淋巴组织细胞增多症病例报告及文献综述。

IF 0.7

Case Reports in Oncology Pub Date : 2024-07-30 eCollection Date: 2024-01-01 DOI: 10.1159/000539955

Michael Herman, Andrea Lee, Sandra Fawcett, Sanjeev Deodhare

引用次数: 0

Nephroblastoma in Older Adult: Case Report and Review of Literature. 老年人肾母细胞瘤：病例报告和文献综述。

IF 0.7

Case Reports in Oncology Pub Date : 2024-07-30 eCollection Date: 2024-01-01 DOI: 10.1159/000540279

Ricardo Fernández-Ferreira, Jose Manuel Torres-Zazueta, César Martínez-Medrano, Adrián Meléndez-Mendoza, Sonia Tavares-García, María Alejandra Muñoz Rubiano, Gredel Portela-Rubio, Julieta Robles-Castro, Jorge Alberto Robles-Aviña, Jose Manuel Ruiz Morales

{"title":"Nephroblastoma in Older Adult: Case Report and Review of Literature.","authors":"Ricardo Fernández-Ferreira, Jose Manuel Torres-Zazueta, César Martínez-Medrano, Adrián Meléndez-Mendoza, Sonia Tavares-García, María Alejandra Muñoz Rubiano, Gredel Portela-Rubio, Julieta Robles-Castro, Jorge Alberto Robles-Aviña, Jose Manuel Ruiz Morales","doi":"10.1159/000540279","DOIUrl":"10.1159/000540279","url":null,"abstract":"Introduction: Nephroblastoma, or Wilms' tumor, is a malignant renal neoplasm commonly found in children, is extremely rare in adults representing only 0.5% of all renal neoplasms. Adult Wilms tumor is rare, to our knowledge fewer than 300 cases have been reported in the English literature to date. However, in older adults after 60 years of age, only less than 45 cases have been reported. For this reason, treatment guidelines in adults still are lacking. Prognosis in nephroblastoma for adult patients is found to be worse than in children.Case presentation: We report the case of a 65-year-old female with lumbar fossa mass, flank pain and hematuria, and pathologic diagnosis of Wilms tumor. We performed nephrectomy. No adjuvant treatment was given. Our patient remains asymptomatic and without evidence of recurrence 12 months after the surgery.Conclusion: Nephroblastoma in the elderly presents different clinical behavior and prognosis compared to nephroblastoma in children.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastatic Pancreatic Adenocarcinoma Downstaged to T0N0 with Chemotherapy and Targeted Therapy, Confirmed by Surgical Pathology: A Case Report. 转移性胰腺腺癌经化疗和靶向治疗降期至 T0N0，并经手术病理证实：病例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2024-07-29 eCollection Date: 2024-01-01 DOI: 10.1159/000539776

Bach Ardalan, Alan Livingstone, Dido Franceschi, Danny Sleeman, Jose Azqueta, Rosali Gonzalez, Jonathan England

{"title":"Metastatic Pancreatic Adenocarcinoma Downstaged to T0N0 with Chemotherapy and Targeted Therapy, Confirmed by Surgical Pathology: A Case Report.","authors":"Bach Ardalan, Alan Livingstone, Dido Franceschi, Danny Sleeman, Jose Azqueta, Rosali Gonzalez, Jonathan England","doi":"10.1159/000539776","DOIUrl":"10.1159/000539776","url":null,"abstract":"Introduction: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive human tumor that is typically diagnosed at a later stage when surgery is not possible.Case presentation: We report the case of a 62-year-old woman who presented to the emergency department with abdominal pain. Computed tomography (CT) revealed a solitary hepatic lesion and a pancreatic body lesion. The pancreatic body lesion was biopsied endoscopically, and a tissue diagnosis was obtained to confirm the diagnosis of PDAC. She was then treated with 12 cycles of FOLFIRINOX with stable disease on CT. Due to the history of a hepatic lesion, she received 11 cycles of gemcitabine/Abraxane and a combination of a MEK inhibitor, Mekinist, and a BRAF inhibitor, BRAFTOVI. Subsequently, the patient underwent a liver biopsy. The biopsy result was negative, and the tumor was deemed resectable. The patient underwent a distal pancreatectomy. Surgical pathology demonstrated a 1.1-cm low-grade papillary mucinous neoplasm with negative margins and lymph nodes, staged T0N0. Adjuvant chemotherapy was not administered.Conclusion: To our knowledge, this is the first report of a patient with metastatic pancreatic adenocarcinoma who received prolonged IV and oral chemotherapy. At the time of the operation, the pathological stage was T0N0. The patient has recently been seen 9 months after surgery with no evidence cancer recurrence. Additionally, ctDNA remains negative.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lung Adenocarcinoma Presenting as Early Cardiac Tamponade: A Case Report. 肺腺癌表现为早期心脏填塞：病例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2024-07-25 eCollection Date: 2024-01-01 DOI: 10.1159/000540183

Volha Chapiolkina, Homa Saadati, Nehemias Antonio Guevara-Rodriguez, Garry Francis-Morel

{"title":"Lung Adenocarcinoma Presenting as Early Cardiac Tamponade: A Case Report.","authors":"Volha Chapiolkina, Homa Saadati, Nehemias Antonio Guevara-Rodriguez, Garry Francis-Morel","doi":"10.1159/000540183","DOIUrl":"10.1159/000540183","url":null,"abstract":"Introduction: Lung cancer remains the most common cause of cancer death in the USA and worldwide despite continued advances in lung cancer screening and treatment. Pericardial effusion (PerF) has been found in up to 50% of postmortem patients with cancer; lung and breast cancers are the most frequent malignancies. Furthermore, it is a sign of poor outcomes with fewer than 5 months of survival. Nevertheless, PErF with or without tamponade as a presentation of lung cancer is uncommon.Case presentation: We present a 72-year-old male without medical history who presented with 1 month of cough with white sputum and shortness of breath, progressively worsening, associated with weight loss (20 pounds). Further studies demonstrated early cardiac tamponade secondary to malignancy.Conclusion: Cardiac tamponade can arise secondarily from various etiologies and have different presentations depending on the cause. In general, it is a slowly developing and clinically silent disease process. Therefore, malignant PerFs can rarely present with hemodynamic instability and be the initial manifestation of an underlying malignancy. Our case review presents a rare case of metastatic lung adenocarcinoma manifesting as early symptomatic cardiac tamponade and as an emergency. The results might be life-threatening if this presentation is not recognized and managed appropriately. Clinicians must be aware of such atypical presentations of thoracic malignancies to take action adequately.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Case of Hepatocellular Carcinoma after Treatment for Chronic Myeloid Leukemia in a Patient without Liver Disease. 一例无肝病患者在接受慢性粒细胞白血病治疗后出现肝细胞癌的病例。

IF 0.7

Case Reports in Oncology Pub Date : 2024-07-25 eCollection Date: 2024-01-01 DOI: 10.1159/000540260

Darshankumar M Raval, Ricardo J Pagán, Shayan Butt, Libardo Rueda Prada

{"title":"A Case of Hepatocellular Carcinoma after Treatment for Chronic Myeloid Leukemia in a Patient without Liver Disease.","authors":"Darshankumar M Raval, Ricardo J Pagán, Shayan Butt, Libardo Rueda Prada","doi":"10.1159/000540260","DOIUrl":"10.1159/000540260","url":null,"abstract":"Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the reciprocal translocation of chromosomes 9 and 22, which leads to a chimeric gene product known as BCR-ABL. Some studies have shown a higher incidence of secondary malignancies than the one seen in the general population in patients with CML. Hepatocellular carcinoma (HCC) is rarely reported in association with CML and/or CML-related treatment.Case presentation: We describe a case of a patient with no history of liver disease and CML on imatinib for 10 years, who presented with worsening right upper quadrant abdominal pain. Imaging revealed a large hepatic mass highly suspicious of malignancy that later was confirmed to be HCC after biopsy. The patient was bracketed with advanced stage HCC (BCLC stage C) and given her advanced age and poor performance status; palliative care was offered.Conclusion: Patients with CML have a common association with secondary malignancies. This is the first case report based on our extensive review of available literature that HCC was diagnosed in a patient with CML on treatment with imatinib without any clear or usual underlying cause.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Case Report of Complete Response to Olaparib in a Patient with Breast Cancer Brain Metastases. 乳腺癌脑转移患者对奥拉帕利完全应答的病例报告

IF 0.7

Case Reports in Oncology Pub Date : 2024-07-20 eCollection Date: 2024-01-01 DOI: 10.1159/000540257

Kazuki Asazuma, Akihiko Shimomura, Yukino Kawamura, Tomoko Taniyama, Chikako Shimizu

{"title":"Case Report of Complete Response to Olaparib in a Patient with Breast Cancer Brain Metastases.","authors":"Kazuki Asazuma, Akihiko Shimomura, Yukino Kawamura, Tomoko Taniyama, Chikako Shimizu","doi":"10.1159/000540257","DOIUrl":"10.1159/000540257","url":null,"abstract":"Introduction: Breast cancer is the second most common cause of central nervous system (CNS) metastases. It has been shown that the median time from breast cancer diagnosis to CNS metastasis is 30.9 months and that the overall median survival after metastasis is extremely poor at 6.8 months. Although treatment options for ErbB2 Receptor Tyrosine Kinase 2 (ERBB2)-positive breast cancer brain metastasis (BCBM) have been reported, effective treatment options for ERBB2-negative BCBM, which has one of the worst prognoses, are limited. Olaparib is one of the standard treatments for germline BRCA1/2 mutated (gBRCA1/2mt), ERBB2-negative, metastatic, or recurrent breast cancer. However, there is minimal existing evidence to evaluate the efficacy of olaparib in BCBM.Case presentation: In our report, we assessed the case of a Japanese woman in her early 30s, ERBB2-negative, gBRAC2mt-positive BCBM, who achieved a complete response and prolonged progression-free survival of 9 months after the initiation of treatment with olaparib.Conclusions: Thus, our case report demonstrated the significant efficacy of olaparib in BCBM treatment. Furthermore, we highlighted the need for more studies to investigate the efficacy of olaparib and explore the efficacy of poly ADP ribose polymerase inhibitors in BCBM.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New Perspectives in the Treatment of Inflammatory Myofibroblastic Tumor with ALK Translocation: Case Report. 治疗伴有 ALK 转座的炎性肌纤维母细胞瘤的新视角：病例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2024-07-20 eCollection Date: 2024-01-01 DOI: 10.1159/000539739

Johana Benedetti Pedroza, Irene Carrasco García, Gala Martínez Bernal, Isabel Miras Rodriguez

引用次数: 0

Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports. 曾接受过治疗的携带 IDH1 R132 突变的晚期肝内胆管癌患者对伊沃西地尼的持续临床反应：两个病例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2024-07-15 eCollection Date: 2024-01-01 DOI: 10.1159/000539665

Christian Müller, Sabine Franke, Timo Reisländer, Verena Keitel, Marino Venerito

{"title":"Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports.","authors":"Christian Müller, Sabine Franke, Timo Reisländer, Verena Keitel, Marino Venerito","doi":"10.1159/000539665","DOIUrl":"10.1159/000539665","url":null,"abstract":"Introduction: Patients with progressing intrahepatic cholangiocarcinoma (iCCA) harboring an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib showed a median progression-free survival (PFS) benefit of 1.3 months compared to placebo in the phase 3 ClarIDHy trial.Case presentations: We describe 2 consecutive patients with previously treated unresectable and metastatic iCCA harboring an IDH1 R132 mutation who achieved durable clinical responses with ivosidenib 500 mg once daily for >12 months until disease progression. In one case with a mixed response, a single progressive liver metastasis was additionally treated locally with interstitial brachytherapy, while ivosidenib was continued until further progression. Ivosidenib therapy resulted in long-term disease control with PFS of 20 and 13 months and duration of treatment of 26 and 13 months, respectively, with no relevant side effects.Conclusion: Patients with unresectable or metastatic IDH1-mutated iCCA can achieve sustained clinical responses for >12 months with ivosidenib. No new safety signals were observed during long-term treatment with ivosidenib.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum B-Cell Maturation Antigen Reflects Disease Status in a Patient Who Developed Nonsecretory Multiple Myeloma: A Case Report. 血清 B 细胞成熟抗原反映非分泌型多发性骨髓瘤患者的疾病状态：病例报告。

IF 0.7

Case Reports in Oncology Pub Date : 2024-07-12 eCollection Date: 2024-01-01 DOI: 10.1159/000539814

Ryan Danis, Bernard Regidor, Sean Bujarski, Scott Jew, Marissa-Skye Goldwater, Regina Swift, Benjamin Mark Eades, Marsiye Emamy-Sadr, Ashley Del Dosso, James Berenson

{"title":"Serum B-Cell Maturation Antigen Reflects Disease Status in a Patient Who Developed Nonsecretory Multiple Myeloma: A Case Report.","authors":"Ryan Danis, Bernard Regidor, Sean Bujarski, Scott Jew, Marissa-Skye Goldwater, Regina Swift, Benjamin Mark Eades, Marsiye Emamy-Sadr, Ashley Del Dosso, James Berenson","doi":"10.1159/000539814","DOIUrl":"10.1159/000539814","url":null,"abstract":"Introduction: Multiple myeloma (MM) is an incurable bone marrow (BM)-based cancer involving clonal plasma cells. Most patients show elevated levels of serum monoclonal protein (sMP) and kappa or lambda serum free light chains (sFLCs) at diagnosis. However, around 1-2% of patients, termed nonsecretory, do not produce these biomarkers. As the disease progresses, more patients may become unevaluable using conventional markers, requiring invasive and expensive procedures like BM biopsies and positron emission tomography-computed tomography (PET-CT) scans for assessment and highlighting the need for alternative methods to monitor disease progression.Case presentation: We present a case report of an MM patient who developed nonsecretory disease during his second line of treatment when he complained of new rib pain; progressive disease was then confirmed on a PET-CT scan. The patient showed an increase in his serum B-cell maturation antigen (sBCMA) levels whereas his conventional myeloma markers did not detect disease activity (sMP remained undetectable and involved sFLC level was normal). After starting a new treatment regimen, his rib pain disappeared, PET-CT scan improved, and sBCMA levels decreased. Upon relapse, he developed increased rib pain with a rising sBCMA level; his conventional myeloma markers did not detect disease activity. After changing to a new regimen, his rib pain improved, and this was accompanied by a decrease in his sBCMA levels.Conclusion: Thus, this case exemplifies the potential for sBCMA to provide a non-invasive method for monitoring MM patients who develop nonsecretory disease.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Pleural Origin of Retiform Hemangioendothelioma: An Unusual Origin of a Rare Diagnosis. 网状血管内皮瘤的胸膜起源：罕见诊断的不寻常起源

IF 0.7

Case Reports in Oncology Pub Date : 2024-07-12 eCollection Date: 2024-01-01 DOI: 10.1159/000539771

Hidayat Ullah, Imran Khan, Aria Khan, Apoorva Tangri, Saral Lamichhane, Shahzaib Maqbool, Abdulqadir J Nashwan

{"title":"The Pleural Origin of Retiform Hemangioendothelioma: An Unusual Origin of a Rare Diagnosis.","authors":"Hidayat Ullah, Imran Khan, Aria Khan, Apoorva Tangri, Saral Lamichhane, Shahzaib Maqbool, Abdulqadir J Nashwan","doi":"10.1159/000539771","DOIUrl":"10.1159/000539771","url":null,"abstract":"Introduction: Vascular malignancies are categorized into benign hemangiomas, malignant angiosarcomas, and tumors of intermediate malignancy. Retiform hemangioendothelioma (RH) is one of the rare diagnoses belonging to the class of intermediate malignancies that was initially diagnosed.Case presentation: In this case report, we have reported a rare case of RH, a locally aggressive, vascular tumor of malignant potential presenting at an unusual site. The most observed locations of this soft tissue tumor are skin and subcutaneous tissues of extremities; however, this case of RH was observed in an unusual site called pleura, which is a rare occurrence related to this tumor. The presence of cell surface markers like CD31 and ERG of vascular and endothelial origin and the presence of hobnail appearance of endothelial channels on the biopsy profile supported the vascular origin of the tumor; the clinical features and imaging studies further confirmed the diagnosis of RH.Conclusion: In this case report, a rare case of RH with an unusual site of origin was highlighted. RH is a vascular neoplasm; commonly observed sites of this vascular tumor were skin and subcutaneous tissue of the extremities; however, in this case, the site was unusually different, which was the pleura of the left lung.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0